X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (317) 317
breast cancer (301) 301
oncology (301) 301
index medicus (299) 299
female (291) 291
breast neoplasms - drug therapy (219) 219
postmenopausal women (170) 170
cancer (152) 152
chemotherapy (149) 149
endocrine therapy (135) 135
breast neoplasms - pathology (123) 123
care and treatment (117) 117
double-blind (109) 109
metastasis (99) 99
everolimus plus exemestane (89) 89
antineoplastic agents - therapeutic use (87) 87
aromatase inhibitors (78) 78
pharmacology & pharmacy (73) 73
randomized-trial (73) 73
tamoxifen (71) 71
breast neoplasms - metabolism (69) 69
medicine & public health (68) 68
treatment outcome (66) 66
1st-line treatment (63) 63
antineoplastic agents, hormonal - therapeutic use (61) 61
aged (60) 60
health aspects (60) 60
hematology, oncology and palliative medicine (60) 60
antineoplastic combined chemotherapy protocols - therapeutic use (59) 59
phase-ii trial (59) 59
trastuzumab (59) 59
drug therapy (57) 57
middle aged (57) 57
estrogen (56) 56
metastatic breast cancer (55) 55
open-label (54) 54
clinical trials (53) 53
research (53) 53
phase-iii trial (52) 52
review (52) 52
everolimus (51) 51
aromatase inhibitors - therapeutic use (50) 50
cancer therapies (48) 48
analysis (47) 47
clinical trials as topic (46) 46
neoplasm metastasis (46) 46
receptor, erbb-2 - metabolism (45) 45
estrogen-receptor (42) 42
therapy (42) 42
adult (41) 41
breast neoplasms - genetics (41) 41
breast neoplasms - therapy (41) 41
adjuvant chemotherapy (39) 39
fulvestrant (38) 38
chemotherapy, adjuvant (37) 37
disease-free survival (37) 37
molecular targeted therapy (37) 37
receptors, estrogen - metabolism (37) 37
women (37) 37
letrozole (36) 36
plus (36) 36
randomized phase-ii (36) 36
premenopausal women (35) 35
first-line therapy (34) 34
prognosis (34) 34
tumors (34) 34
estrogen plus progestin (33) 33
plus zoledronic acid (33) 33
combination (32) 32
obstetrics & gynecology (32) 32
tamoxifen - therapeutic use (32) 32
anastrozole (31) 31
breast neoplasms - mortality (31) 31
drug resistance, neoplasm (31) 31
phase-iii (31) 31
randomized controlled trials as topic (31) 31
trial (31) 31
aromatase inhibitor (30) 30
growth-factor receptor (30) 30
postmenopause (30) 30
progression-free survival (30) 30
survival (30) 30
antineoplastic agents (29) 29
plus exemestane (29) 29
quality of life (29) 29
quality-of-life (29) 29
follow-up (28) 28
adjuvant treatment (27) 27
animals (27) 27
antineoplastic agents - pharmacology (27) 27
development and progression (27) 27
surgical adjuvant breast (27) 27
antineoplastic agents - adverse effects (26) 26
internal medicine (26) 26
medicine, general & internal (26) 26
neoplasm staging (26) 26
targeted therapy (26) 26
aged, 80 and over (25) 25
article (25) 25
fulvestrant 500 mg (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 10/2016, Volume 163, pp. 1 - 11
Journal Article
Targeted Oncology, ISSN 1776-2596, 2018, Volume 13, Issue 5, pp. 641 - 648
Background Treating breast cancer patients with everolimus and exemestane can be challenging due to toxicity and suboptimal treatment responses. Objective We... 
MAMMALIAN TARGET | PLUS EXEMESTANE | SOLID TUMORS | EFFICACY | ONCOLOGY | MTOR INHIBITOR EVEROLIMUS | SAFETY | PHASE-I | ENDOCRINE MONOTHERAPY | PET | CHEMOTHERAPY | Cancer patients | Care and treatment | Patient outcomes | Breast cancer | Angiogenesis inhibitors | Drug therapy | Cancer
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 10/2015, Volume 42, Issue 10, pp. 1319 - 1321
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2005, Volume 11, Issue 2, pp. 918s - 924S
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2008, Volume 19, Issue 8, pp. 592 - 597
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 04/2019, Volume 62, Issue 7, pp. 3636 - 3657
C-6 alpha and C-7 alpha androstanes were studied to disclose which position among them is more convenient to functionalize to reach superior aromatase... 
EVEROLIMUS PLUS EXEMESTANE | CELLS | DESIGN | CHEMISTRY, MEDICINAL | ADVANCED BREAST-CANCER | BIOLOGICAL-ACTIVITY | X-RAY | LIGAND | BINDING-SITES | ESTROGEN-RECEPTOR | HORMONES
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article